Two patients with leukemia experienced profound thrombocytopenia and refractoriness to platelet transfusion during vancomycin treatment. In one patient, withdrawal of drug and administration of platelet transfusions restored platelet counts to near normal levels (-100 x 1 o 9 /~) , however, subsequent challenge with vancomycin due to recurring infection again precipitated severe thrombocytopenia (platelets 110 x 109/L) and life-threatening hemorrhagic symptoms. Potent vancomycin-dependent antiplatelet antibodies were detected in the serum of both patients during the refractory period using staphylococcal protein A rosette formation. Employing a monoclonal antibodyantigen capture enzyme-linked immunosorbent assay EFRACTORINESS TO platelet transfusion is a signif-R icant problem in the management of leukemia patients. There are many factors associated with a lack of response to platelet transfusions in these patients, including splenectomy,' disseminated intravascular coagulation,' sepsis,' amphotericin B, palpable spleen, bone marrow transplantation: HLA and the presence of leukocytes in platelet transfusion units.' Several studies show a correlation between alloimmunization, production of HLA antibodies, and refractoriness to platelet transf~sion.~-~ Although the refractory state can be provoked by a variety of different causes,'.' refractoriness to platelet transfusion remains unexplained in many patients. Most patients with leukemia receive vancomycin, gentamycin, amphotericin B, and other drugs as standard antibiotic and antifungal therapy. Frequently, these drugs are given concomitantly with platelets. The possibility that some patients may develop drug-dependent antibodies responsible for shortened platelet survival is often overlooked or not considered a t all. Of particular interest is the recent observation that administration of amphotericin B is significantly correlated with failure to respond to platelet transfusions: No mechanism was offered for the role of amphotericin B in provoking refractoriness to platelet transfusion. Thus, although substantial evidence exists that HLA antibodies are associated with refractoriness to platelet transfusion in alloimmunized leuke-
mia patients, it is not known whether drug-dependent antibodies may be involved in this process. In the present report, we describe two patients with leukemia who developed vancomycin-dependent antibodies that were directly associated with episodes of severe thrombocytopenia and refractoriness to platelet transfusion.
METHODS

Patient Histories
In September of 1987, a 73-year-old white female (KW) was diagnosed with acute nonlymphocytic leukemia (ANLL) type
MI. Laboratory tests at admission revealed counts as follows:
hemoglobin at 9.4 g/dL; platelets at 90 x 109/L; and white blood cells (WBCs) at 19.9 x 109/L, with 9% circulating blasts and 90% blasts in the bone marrow. The patient also had severe pneumonia and was treated with vancomycin, ticarcillin, and erythromycin. On day 10, she became severely thrombocytopenic (platelets at 14 x 109/L, Fig 1) and vancomycin, ticarcillin and erythromycin were withdrawn. Platelets were administered, and she achieved a onehour posttransfusion corrected count increment (CCI) of 10,000 (Table 1 ) with a subsequent platelet count of -100 x 109/L. However, due to recurring infection, vancomycin was again started (day 18), resulting in a rapid drop in the platelet count ( < l o x 109/L, days 20 and 21). Vancomycin was discontinued, and subsequent transfusions failed to achieve a detectable CCI except on day 28 after transfusion of HLA-matched platelets. Serum obtained on day 23 contained multiple HLA class I antibodies. Arabinomycin C (3 g/m*, total = 4.5 g twice a day for 6 days) and intrathecal methotrexate (6 mg/m2, total = 10 mg/d for 2 days) were administered for treatment of the patient's ANLL. Although achieving remission (determined at autopsy) in her leukemia and resolution of the pneumonia, the patient again became febrile and developed profound neutropenia with a neutrophil count of only 0.6 x 109/L (day 51). The patient died on day 52 of cardiopulmonary arrest resulting from pathologic changes in her lungs, probably due to an infectious agent, though all cultures at autopsy were negative.
In October of 1988, a 31-year-old white male (DA) was diagnosed with acute lymphocytic leukemia (ALL) of T cell origin. Laboratory tests at admission revealed counts as follows: hemoglobin at 15.9 g/dL; platelets at 17 x 109/L; and WBCs at 57 x 109/L, with 61% blasts. Due to a fever on day 11, the patient was started on vancomycin, ticarcillin, gentamycin, amphotericin B, and nystatin. Platelet transfusions achieved significant CCI (Table 1) HLA-matched platelets (day 22). Serum obtained on day 25 contained multiple class I HLA antibodies. The patient was infused with high dose intravenous (IV) IgG (20 g every 12 hours), which produced a marked rise in platelets and a posttransfusion CCI of 7,700 (day 29). Bone marrow exam on day 25, following an eight-day ALL treatment course (daunorubicin, 60 mg/m2, total = 130 mg on days 3 to 5; arabinomycin C, 54 mg IV push followed by 200 mg/m2, total = 432 mg on days 3 to 7; 6-thioguanine, 102 mg/m2, total = 220 mg twice daily on days 3 to 7; vincristine, 2 mg on days 3 and 10; and prednisone, 60 mg/m2, total = 130 mg on days 3 and 9), indicated that the patient was in remission. Unfortunately, the patient developed adult respiratory distress syndrome and died (day 3 1) of cardiopulmonary arrest resulting from respiratory insufficiency that was complicated by left tension pneumothorax (confirmed at autopsy). 
Materials
Platelets
Platelets for use in antibody testing were obtained from normal volunteers who gave informed consent in accordance with guidelines established by the University of Minnesota Committee on the Use of Human Subjects in Research. Platelets deficient in glycoproteins (GP) IIb and IIIa were obtained from an individual with Glanzmann's thrombasthenia, who was kindly referred to us by Dr James White, Minneapolis, MN. Posttransfusion CCI and their significance were determined as described." Platelets transfused were either single random donor units (R), random donor pheresis units (PH), related family member pheresis units (F-PH), or HLA, A or B matched grades" obtained from pheresis units (HLA-PH).
Monoclonal Antibody-SpeciJic Immobilization of Platelet Antigen Assay
The monoclonal antibody-specific immobilization of platelet antigen (MAIPA) assay was performed essentially as described." The murine monoclonal antibodies (MoAbs) used for platelet detection were as follows: 6D1 and lOE5 (kindly provided by Dr Barry Coller, State University of New York, Stony Brook) directed against GPIb, of the GPIb/IX complex" and GPIIb, of the intact GPIIb/IIIa ~o m p l e x , '~ respectively; AP3 (kindly provided by Dr Peter Newman, The Blood Center of Southeastern Wisconsin, Milwaukee) directed against GPIIIa'4; and FMC25 (kindly provided by Dr Michael Berndt, Westmead Centre, Australia) directed against GP1X.l' Vancomycin was used at a final concentration of 300 pmol/L in all incubations and washes requiring drug. In some experiments, serum (45 pL) was preadsorbed two consecutive times with normal or Glanzmann's thrombasthenic platelets (5 x lo*) in the presence of 300 pmol/L vancomycin or phosphate-buffered saline (PBS) for 30 minutes at room temperature. These serum samples were then tested by MAIPA assay using normal platelets. Controls included use of normal human serum in place of patients' (DA and KW) sera and serum from four patients refractory to platelet transfusion who had HLA, but not vancomycin-dependent, antibodies.
Staphylococcal Protein A Rosette Assay
This procedure was performed essentially as de~cribed'~.'' using vancomycin at a final concentration of 300 pmol/L and employing the following modification. A semi-quantitative scoring system was utilized by determining the percentage of surface area of each protein A bead coated with adherent platelets for 30 beads per well. The scores of triplicate wells were determined followed by calculation of the mean * SD. Each bead was scored according to the following scheme: 75% to 100% = 4 + , 50% to 75% = 3 + , 25% to 50% = 2 + , 10% to 25% = 1 + , and 110% = 0. Presence of a drug-dependent antibody in a particular serum sample was defined by a mean rosette score obtained in the presence of drug that was significantly greater than the score obtained in the presence of PBS.
Statistical significance was determined by Student's t test. A P value <.05 was considered a positive result. Controls included use of normal human serum in place of patients' (DA and KW) sera and serum from seven nonthrombocytopenic (platelet counts z 100 x 1 0~1~) patients receiving vancomycin continuously or intermittently (three or more times) for at least 10 to 14 days.
In some experiments, the vancomycin concentration in serum samples was determined by fluorescent polarization. This procedure was performed by the University Hospital's Toxicology Laboratory using a method developed by Abbott Laboratories (Chicago, IL).
RESULTS
Antibody Detection
Examination of patient KW's platelet counts (Fig 1) suggested that vancomycin may have been involved in provoking the initial two episodes of severe thrombocytopenia prior to administration of chemotherapy. In contrast, this was not so obvious for patient DA. In order to determine whether the cause of thrombocytopenia and subsequent refractoriness to platelet transfusion might be related to an immune process, we screened the patients' serum for vancomycin-dependent antibodies utilizing protein A-Sepharose rosette formation. Serum from each patient (KW, days 21 to 28 and DA, days 25 to 28) showed strongly enhanced rosette formation in the presence of vancomycin when compared to reactions performed in the presence of PBS ( Table 2) . None of the other drugs received by the patients during vancomycin treatment when tested with their sera elicited any drug-dependent antibody activity, nor did serum from seven nonthrombocytopenic patients being similarly treated with vancomycin (data not shown). Because results performed with DA's serum and PBS were significantly higher than control values, this serum was assayed for residual drug levels and found to have 16 pmol/L vancomycin. After reduction of the vancomycin concentration to less than 4 pmol/L by dialysis, the rosette score with PBS decreased by 62%, but the net difference in scores between vancomycin and PBS before and after dialysis remained the same (-30).
Glycoprotein Binding Specificity
MAIPA assay was used to determine the platelet G P binding site(s) for attachment of the drug-dependent antibodies, employing MoAbs directed against GPIb,, GPIX, GPIIb,, and GPIIIa. The serum of both patients contained IgG vancomycin-dependent antibodies that reacted strongly with only GPIIb and/or GPIIIa (Fig 2) . The variability in antibody binding between DA and KW observed with AP3 and 1 OE5 suggests that these vancomycin-dependent antibodies react with different epitopes on the GPIIb and/or GPIIIa molecules. In the absence of vancomycin, the antibodies failed to react or reacted only very weakly with the GPs being examined. However, there was modest reactivity of DA's antibody in the presence of PBS using AP3, which was probably due to residual vancomycin in the serum (discussed above). No significant binding of IgG was observed in the presence of vancomycin or PBS using normal human serum, and there was no effect of vancomycin on the binding of HLA antibodies to platelets using serum from four patients who had potent HLA antibody activity and who were refractory to platelet transfusion (data not shown).
Sufficient serum was available from KW to verify the GPIIb and/or GPIIIa binding specificity of the vancomycindependent antibody using Glanzmann's thrombasthenic platelets known to be deficient in these GPs. By the rosette assay, KW's vancomycin-dependent antibody bound to normal but not Glanzmann's thrombasthenic platelets (Table 3) . The rosette formation observed in the presence of PBS with these platelets and KW serum when compared with normal human serum (47 f 10 versus 15 L 11 [P < .05], respectively) was most likely due to HLA antibodies in KW's serum (see Methods). That drug-dependent antibody binding to the Glanzmann's thrombasthenic platelets could be demonstrated was evident by their reaction with a quininedependent antibody directed against GPIb and/or GPIX." Removal of KW's vancomycin-dependent antibody by adsorption with normal but not Glanzmann's thrombasthenic platelets in the presence of vancomycin (Fig 3) provided further evidence for the GPIIb and/or GPIIIa binding specificity of this antibody. The partial reduction in the vancomycin-dependent antibody content of KW's serum by adsorption with normal platelets and PBS was most likely due to the presence of residual vancomycin in the patient's serum.
Other Studies
KW's vancomycin-dependent antibody possessed several characteristics similar to those observed for the classic quinine-and quinidine-dependent antibodies. The vancomy- cin-dependent antibody failed to react with platelets that had been pretreated with vancomycin and then washed, and excess exogenous drug was required for antiplatelet activity. The antibody also exhibited increased reactivity as a function of increasing vancomycin concentration. Optimum reactions by MAIPA assay were achieved at vancomycin concentrations greater than 100 pmol/L (Fig 4) . Furthermore, the patient's antibody was specific for vancomycin because it did not react with platelets in the presence of an irrelevant drug, such as, quinidine. Finally, the vancomycin-dependent antibody reacted equally well with and platelets, thus demonstrating a lack of any selectivity for these alloantigenic determinants known to reside on GPIIIa19 (data not shown).
DISCUSSION
There are two major findings from this investigation: (1) drug-dependent antibodies are associated with thrombocytopenia and refractoriness to platelet transfusion in certain leukemia patients; and (2) vancomycin-dependent antiplatelet antibodies have been demonstrated for the first time.
Refractoriness to platelet transfusion in leukemia patients recovering from bone marrow transplantation is a common and serious problem. Although many factors may account for the refractory state, alloimmunization due to HLA antigen incompatibility is frequently implicated as a primary cause>-* More recently, autoantibodies reactive with platelets in post bone marrow transplant patients who developed graft-versus-host disease appeared to contribute to persistent thrombocytopenia among these individuals." However, we are unaware of any studies that implicate drug-dependent antibodies as causative agents in this process. Our findings provide evidence that vancomycin, a drug commonly administered to many leukemia patients, can be associated with immune-mediated thrombocytopenia and poor responsiveness to transfused platelets. This is supported by the observation that both patients developed thrombocytopenia and/or refractoriness to platelet transfusion in association with vancomycin therapy; KW's platelet count rose upon removal of the drug and declined when it was reinstituted; and each patient had vancomycin-dependent antibodies directed against GPIIb and/or GPIIIa. We further showed that these antibodies behave similarly to quinine-and quinidine-dependent antibodie~,"-'~ which are frequently implicated in severe drug-induced thrombocytopenia. It may be that HLA antibodies were also responsible for platelet destruction in these two patients because the only significant posttransfusion.CC1 achieved during the refractory periods occurred with HLAmatched platelets ( Table 1) .
Recent studies4 show a correlation between refractoriness to platelet transfusion and use of amphotericin B, although no mechanism was offered for these observations. In this same report, a similar association between vancomycin therapy and refractoriness to platelet transfusion was not found. Although the present study does not address the incidence of drug-dependent antibodies in a large group of patients being treated with vancomycin, our findings underscore the need to investigate the frequency and association of drug-dependent antibodies in patients receiving platelet transfusions. HLA antibodies may mask the presence of platelet-specific and/or drug-dependent antibodies in patient sera, thus hindering detection of the actual or additional agents responsible for platelet destruction. Furthermore, it may not be obvious from clinical criteria that vancomycin is associated with refractoriness to platelet transfusion, as in the case of patient DA (Fig 1) . Other causes of thrombocytopenia, such as sepsis and splenomegaly, may also lead to a reluctance on the part of clinicians to test for an immunologic explanation when platelet counts plummet in patients receiving vancomycin or other drugs. These are important considerations in determining the cause of thrombocytopenia and refractoriness to platelet transfusion because a variety of adverse effects are known for vancomycin, though only a single case of vancomycin-induced thrombocytopenia has been reported24. Platelet-associated IgG was slightly elevated in that study, but no evidence for drug-dependent antibodies was presented. In contrast, many cases of vancomycin- 
